Atherosclerosis
Volume 183, Issue 2 , Pages 238-243 , December 2005

The effects of S-allylmercaptocaptopril, the synthetic product of allicin and captopril, on cardiovascular risk factors associated with the metabolic syndrome

  • Mor Oron-Herman

      Affiliations

    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Chorley Institute of Hypertension Research, Sheba Medical Center, Tel Hashomer 52621, Israel
    • The Institute of Chemical Pathology, Sheba Medical Center, Tel Hashomer, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972 3 5302624; fax: +972 3 5355428.
    • ,
  • Talma Rosenthal

      Affiliations

    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • David Mirelman

      Affiliations

    • Weizmann Institute of Science, Rehovot, Israel
    • ,
  • Talia Miron

      Affiliations

    • Weizmann Institute of Science, Rehovot, Israel
    • ,
  • Aharon Rabinkov

      Affiliations

    • Weizmann Institute of Science, Rehovot, Israel
    • ,
  • Meir Wilchek

      Affiliations

    • Weizmann Institute of Science, Rehovot, Israel
    • ,
  • Ben-Ami Sela

      Affiliations

    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • The Institute of Chemical Pathology, Sheba Medical Center, Tel Hashomer, Israel

Received 19 October 2004 ,Revised 2 March 2005 ,Accepted 14 March 2005.

References 

  1. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1998;37:1595–1607
  2. Sheu WH, Jeng CY, Young MS, Le WJ, Chen YT. Coronary artery disease risk predicted by insulin resistance, plasma lipids, and hypertension in people without diabetes. Am J Med Sci. 2000;319:84–88
  3. Oron-Herman M, Rosenthal T, Sela B-A. Hyperhomocysteinemia as a component of syndrome X. Metabolism. 2003;52:1491–1495
  4. Richer C, Giroux B, Plouin PF, Maarek B, Giudicelli JF. Captopril, pharmacokinetics, antihypertensive and biological effects in hypertensive patients. Br J Clin Pharmacol. 1984;17:243–250
  5. Lam HC, Lee JK, Chiang HT, Chuang MJ, Wang MC. Is captopril-induced improvement of insulin sensitivity mediated via endothelin?. J Cardiovasc Pharmacol. 1998;31(Suppl. 1):S496–S500
  6. Dal Ponte DB, fogt DL, Jacob S, Henriksen EJ. Interactions of captopril and verapamil on glucose tolerance and insulin action in an animal model of insulin resistance. Metabolism. 1998;47:982–987
  7. Duarte J, Martinez A, Bermejo A, et al. Cardiovascular effects of captopril and enalapril in obese Zucker rats. Eur J Pharmacol. 1999;365:225–232
  8. Swislocki AL, Kinney LaPier M, Khuu TL, Fann DT, Tait KY, Rodnick KJ. Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats. Am J Hypertens. 1999;12:581–589
  9. Wiggam MI, Hunter SJ, Atkinson AB, et al. Captopril does not improve insulin action in essential hypertension: a double-blind placebo-controlled study. J Hypertens. 1998;16:1651–1657
  10. Aquel MB, Gharaibah MN, Salhab AS. Direct relaxant effects of garlic juice on smooth and cardiac muscles. J Ethnopharmacol. 1991;33:13–19
  11. Bordia A, Bansal HC, Arora SK, Signh SV. Effect of essential oil of onion and garlic on experimental atherosclerosis in rabbits. Atherosclerosis. 1977;26:379–386
  12. Mansell P, Reckless JPD. Garlic: effects on serum lipids, blood pressure, coagulation, platelet aggregation, and vasodilation. Br Med J. 1991;303:379–380
  13. Mader FH. Treatment of hyperlipidaemia with garlic-powder tablets. Evidence from the German Association of General Practitioners’ multicentric placebo-controlled double-blind study. Arzneimittelforschung. 1990;40:1111–1116
  14. Holzgartner H, Schmidt U, Kuhn U. Comparison of the efficacy and tolerance of a garlic preparation vs. bezafibrate. Arzneimittelforschung. 1992;42:1473–1477
  15. Milner JA. Garlic: its anticarcinogenic and antitumorogenic properties. Nutr Rev. 1996;54:S82–S86
  16. Dausch JG, Nixon DW. Garlic: a review of its relationship to malignant disease. Prevent Med. 1990;19:346–361
  17. Hirsch K, Danilenko M, Giat J, et al. Effect of purified allicin, the major ingredient of freshly crushed garlic, on cancer cell proliferation. Nutr Cancer. 2000;38:245–254
  18. Elkayam A, Mirelman D, Peleg E, et al. The effects of allicin on weight in fructose-induced hyperinsulinemic, hyperlipidemic, hypertensive rats. Am J Hypertens. 2003;16:1053–1056
  19. Miron T, Rabinkov A, Peleg E, Rosenthal T, Mirelman D, Wilchek M. Allylmercaptocaptopril: a new antihypertensive drug. Am J Hypertens. 2004;17:71–73
  20. Jacobsen DW, Gatautis VJ, Green R, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem. 1994;40:873–881
  21. Mirelman D, Wilchek M, Miron T, Rabinkov A, Sivaraman H. Continuous production of allicin PCT publication no. WO 97/39115, 1997.
  22. Rabinkov A, Xiao-Zhu Z, Grafi G, Galili G, Mirelman D. Allin lyase (alliinase) from garlic (Allium sativum): biochemical characterization and cDNA cloning. Appl Biochem Biotechnol. 1994;48:149–171
  23. Schery RW. Plants for man. Englewood, NJ: Prentice-Hall; 1972;
  24. Elkayam A, Mirelman D, Peleg E, et al. The effect of allicin and enalapril in fructose induced hyperinsulinemic hyperlipidemic hypertensive rats. J Hypertens. 2001;14:377–381
  25. Ali M, Al-Qattan K, Al-Enzi F, Khanafer RMA, Mustafa T. Effects of allicin from garlic powder on serum lipids and blood pressure in rats fed with high cholesterol diet. Prostaglandins Leukot Essent Fatty Acids. 2000;64:253–259
  26. Efendy JL, Simmons DL, Campbell GR, Campbell JH. The effect of the aged garlic extract, “Kiolic”, on the development of experimental atherosclerosis. Atherosclerosis. 1997;132:37–42
  27. Abramovitz D, Gavri S, Harats D, et al. Allicin-induced decrease in formation of fatty streaks (atherosclerosis) in mice fed a cholesterol-rich diet. Coron Artery Dis. 1999;10:515–519
  28. Lawson LD, Hughes BG. Inhibition of whole platelet aggregation by compounds in garlic clove extracts and commercial products. Thromb Res. 1992;65:141–156
  29. Miron T, Rabinkov A, Mirelman D, Wilcheck M, Weiner L. The mode of action of allicin: trapping of radicals and interaction with thiol containing proteins. Biochem Biophys Acta. 1998;1379:233–244
  30. Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension. 1987;10:512–516
  31. Oron-Herman M, Sela B-A, Rosenthal T. Risk reduction therapy for syndrome X: comparison of several treatments. Am J Hypertens. 2005;18(3):372–378

PII: S0021-9150(05)00211-X

doi: 10.1016/j.atherosclerosis.2005.03.009

Atherosclerosis
Volume 183, Issue 2 , Pages 238-243 , December 2005

Article Tools

* Image Usage & Resolution